Biography
I obtained my first degree in Human Sciences from the University of Oxford, followed by an MSc and PhD in Infectious Disease Epidemiology at the London School of Hygiene and Tropical Medicine. I worked at the Health Protection Agency and then the University of Bristol before moving to Cambridge in January 2013. I work in the Disease Dynamics Unit in the Department of Veterinary Medicine.
Research
Research Interests
My research concentrates on understanding the epidemiology of vaccine-preventable diseases and the impact of immunisation. The majority of my work is on meningococcal infection, and I conduct studies in Europe and Africa. I am also involved in research on group B streptococcal, pneumococcal, rotavirus, norovirus and HPV infections.
I use a range of methods including analysis of large databases, systematic reviews, prospective clinical/ field studies, health economics, seroprevalence studies and mathematical modelling. I am most interested in applying these methods to research questions of direct relevance for vaccine policy.
Publications
Karachaliou A, Conlan AJ, Preziosi MP, Trotter CL. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt. Clin Infect Dis. 2015;61 Suppl 5:S594-600. doi: 10.1093/cid/civ508
Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating the cost-effectiveness of universal ‘MenB’ (Bexsero) vaccination in England: a modelling study. BMJ 2014 349 doi: http://dx.doi.org/10.1136/bmj.g5725
Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron M, Ferman F, Page A-L, Djingarey M, Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Caugant DA, Chandramohan D, Hassan-King M, Manigart O, Nascimento M, Woukeu A, Trotter C, Stuart JM, Maiden MCJ, Greenwood B. The impact of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad. Lancet 2014.383:40-7
Rozenbaum M, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Cost-effectiveness of vaccinating risk groups in England against invasive pneumococcal disease using the 13 valent pneumococcal vaccine: an economic analysis. BMJ. 2012 345:e6879
Christensen H, May MT, Bowen L, Hickman M, Trotter CL. A systematic review of meningococcal carriage by age. Lancet Infect Dis 2010, 10:853-61
